



Synairgen plc

May 07 2019

Synairgen making headway

- **Focused on respiratory disease**
- **Two drug candidates, one being developed in-house the other by a partner**
- **Financially well set to progress its key asset, analyst says**

Respiratory specialist

Synairgen plc (LON:SNG) is currently running a two-part phase II trial evaluating SNG001. This is an inhaled interferon beta drug candidate designed for people with chronic obstructive pulmonary disease (COPD) who are also suffering cold or flu infections.

It has completed the first part of its SG015 study, assessing the safety of the treatment. The second instalment is underway at 13 separate sites.

In an update, the company said the milder start to the current virus season means Synairgen expects the trial to continue into the 2019/20 peak period for cold and flu.

In the latest company release (Mar 14) Synairgen said it is to include patients with more severe chronic obstructive pulmonary disease in the second part of the mid-stage study of its SNG001 drug. The move comes after a successful interim safety review by the independent Data Safety Monitoring Committee which did not identify any safety concerns for patients currently enrolled in the trial.

LOXL2

The company's Australian partner has completed phase I trials and toxicology on a LOXL2 inhibitor developed by Synairgen.


This now paves the way for Pharmaxis to advance discussions with potential partners for the drug, which has been developed to treat non-alcoholic liver disease (NASH) and a rare lung condition.

The company retains a 17% "carried interest" in the asset.

Price: 12.75p

Market Cap: 1

1 Year Share Price Graph



Share Information

Code: SNG

Listing: AIM

52 week	High	Low
	27p	10p

Sector: Pharma & Biotech

Website: <https://www.synairgen.com>

Company Synopsis:

*Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on severe asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease. *

Author:

Proactive Investors

+44(0)1202770386

action@proactiveinvestors.com



Synaigen's BioBank

Over the years, Synaigen has accumulated an extensive bank comprised of blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma or COPD. Using this resource, the company has developed a number of advanced tissue models.

It uses these models to:

- Discover novel drug targets
- Identify disease-related lesions and underlying molecular mechanisms
- Conduct proof of concept testing and validation of novel drug targets
- Conduct screening assays for novel drug targets and lead target selection
- Provide support for clinical trial activities

Financially solid

Brewer's price target for the stock is 54p. The shares are currently changing hands for 15p.



Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com



No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.